Supplementary information, Figure S9



Figure S9 Mouse behavior tests for mice after stereotaxic injection of indicated AAVs or those receiving oral intake of ATRA. (**A**) Time spent in the center area among mice injected with different AAVs encoding EGFP, UBE3A, and T508E in open field test. (**B**) The percentages of distances traveled in center of total areas for the mice injected with different AAVs encoding EGFP, UBE3A, or T508E in open field test. (**C**) Latencies to fall were compared among mice injected with the different AAVs in rotarod test. (**D**) For mice injected with UBE3A-encoding AAV, time spent in the center in open field test

was compared between those upon oral administration with vehicle and ATRA (n = 9). (**E**) For mice injected with UBE3A-encoding AAV, the percentages of distances traveled in the center of total areas in open field test were compared between those receiving vehicle and ATRA (n = 9). (**F**) For mice injected with UBE3A-encoding AAV, latencies to fall in rotarod test were compared between those received vehicle and ATRA (n = 10). (**G**) Time spent in self-grooming was compared in wild-type mice upon treatment of vehicle or ATRA (n = 10). (**H**, **I**) Time spent investigating Stranger I over Object **(H)**, or Stranger I over Stranger II **(I)** was compared between the wild-type mice administered with vehicle and ATRA (n = 10). (**J**, **K**) In wild-type mice receiving treatment of vehicle or ATRA, time spent in center **(J)**, and distances traveled in center (% of total) **(K)** in open field test were recorded and compared (vehicle, n = 9; ATRA, n = 10). (**L**) Latencies to fall in rotarod test were compared between the wild-type mice administered with vehicle and ATRA (vehicle, n = 9; ATRA, n = 10). **(A-C)** n.s., not significant (one-way ANOVA, with Bonferroni *post-hoc* test); EGFP, n = 10; UBE3A, n = 14; T508E, n = 11; **(D-G)** and **(J-L)** n.s., not significant, **P* < 0.05 (two tailed *t*-test).